PD-L1 mediated T cell inhibition by regulatory plasma cells induced after sepsis and COVID-19

Morgane Gossez,Clara Vigneron,Alexandra Vandermoeten,Margot Lepage,Louise Courcol,Remy Coudereau,Helena Paidassi,Laurent Jallades,Jonathan Lopez,Khalil Kandara,Marine Ortillon,Marine Mommert,Astrid Fabri,Estelle Peronnet,Clemence Grosjean,Marielle Buisson,Anne-Claire Lukaszewicz,Thomas Rimmele,Laurent Argaud,Martin Cour,Benedicte F Py,Olivier Thaunat,Thierry Defrance,guillaume monneret,Fabienne VENET
DOI: https://doi.org/10.1101/2024.08.08.24311630
2024-08-08
Abstract:A better understanding of sepsis-induced immunosuppression pathophysiology is desirable for the development of novel therapeutic strategies to prevent and reduce the rates of secondary infections and their associated mortality. Here we demonstrate that PD-L1+CD44+B220LowCD138+IgM+ regulatory plasma cells (PCs) are induced in a murine model of sepsis-induced immune alterations and in critically ill patients with bacterial sepsis and COVID-19. This was revealed both by detailed analysis of their phenotypical features and gene expression profile and by functional explorations comparing capacity of purified B cells and PCs to suppress T cell proliferation and IFNɣ secretion ex vivo. Sepsis-induced regulatory PCs exerted their suppressive function on T cells through IL-10 production and increased PD-L1 expression independently of regulatory T cells. Our findings thus reveal a novel pathophysiological mechanism of sepsis-induced immunosuppression that involves regulatory PCs. As such, these PCs constitute valid therapeutic targets to improve immune cell functions impaired by sepsis.
Intensive Care and Critical Care Medicine
What problem does this paper attempt to address?